Cantor Fitzgerald Issues Negative Outlook for CATX Earnings

Key Points

• Cantor Fitzgerald has reduced its FY2025 earnings estimate for Perspective Therapeutics, anticipating a loss of ($1.05) per share, down from the previous estimate of ($1.04).
• Several research firms have issued mixed ratings on CATX, with B. Riley setting a price target of $12.00 while Truist Financial lowered theirs to $8.00.
• Perspective Therapeutics has experienced significant institutional investment, with 54.66% of the stock now owned by institutional investors and hedge funds following multiple new acquisitions.

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Research analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Perspective Therapeutics in a report released on Thursday, August 14th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($1.05) for the year, down from their previous forecast of ($1.04). The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. Cantor Fitzgerald also issued estimates for Perspective Therapeutics' FY2026 earnings at ($0.94) EPS.

Other equities analysts have also issued reports about the stock. B. Riley reissued a "buy" rating and issued a $12.00 target price (up from $9.00) on shares of Perspective Therapeutics in a report on Monday, June 23rd. Wedbush reissued an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a report on Monday, June 23rd. Truist Financial dropped their target price on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Saturday, July 12th. Finally, Royal Bank Of Canada raised shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and increased their target price for the stock from $15.00 to $16.00 in a report on Tuesday, June 3rd. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $12.56.

Perspective Therapeutics Price Performance

CATX stock traded up $0.12 during mid-day trading on Monday, hitting $3.68. The stock had a trading volume of 579,561 shares, compared to its average volume of 940,145. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $16.55. The firm has a fifty day simple moving average of $3.79 and a 200 day simple moving average of $2.97.

Institutional Trading of Perspective Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CATX. JPMorgan Chase & Co. grew its holdings in shares of Perspective Therapeutics by 498.3% during the fourth quarter. JPMorgan Chase & Co. now owns 149,045 shares of the company's stock worth $475,000 after purchasing an additional 124,133 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Perspective Therapeutics by 45.7% during the fourth quarter. Wells Fargo & Company MN now owns 26,462 shares of the company's stock worth $84,000 after acquiring an additional 8,294 shares during the last quarter. Mariner LLC bought a new position in shares of Perspective Therapeutics during the fourth quarter worth about $150,000. Walleye Capital LLC raised its position in shares of Perspective Therapeutics by 2,526.2% during the fourth quarter. Walleye Capital LLC now owns 475,792 shares of the company's stock worth $1,518,000 after acquiring an additional 457,675 shares during the last quarter. Finally, Jump Financial LLC bought a new stake in Perspective Therapeutics in the fourth quarter valued at approximately $688,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.